Articles tagged "Liver transplantation"

2015 American Transplant Congress
The Impact of CDC High Risk Donors on Patient and Graft Survival After Liver Transplantation
D. Moonka, A. Yoshida, A. Taylor.
Division of Gastroenterology, Henry Ford Health System, Detroit, MI; Transplant Institute, Henry Ford Health System, Detroit, MI; Department of Public Health Sciences, Henry Ford Health System, Detroit, MI.
We hypothesized that CDC high risk donors (HRD) might be younger than non-HRD and have other characteristics associated with favorable outcomes after liver transplant (LT).…
2015 American Transplant Congress
Single-Center Analysis of Adult, Combined Heart-Liver Transplant (CHLT) Recipients
H. Monsour Jr,¹ M. Boktour,² A. Abimbola,¹ M. Elnemr,¹ S. Gordon Burroughs,² D. Victor III,¹ A. Saharia,² B. Trachtenberg,³ A. Bhimaraj,³ A. Gaber,² J. Estep,³ R. Ghobrial.²
¹Department of Medicine, Houston Methodist Hospital, Houston, TX; ²Department of Surgery, Houston Methodist Hospital, Houston, TX; ³Cardiology Department, Houston Methodist Hospital, Houston, TX.
Background: Combined heart-liver transplantation (CHLT) is life-saving for patients with end-stage heart-liver diseases. This is a review of patients who underwent CHLT at a single-center.Methods:…
2015 American Transplant Congress
Identification of miRNAs Associated With Induced Tolerance to Allografts
M. Vitalone, L. Wei, C. Esquivel, S. Busque, O. Martinez, S. Krams.
Surgery-Transplantation, Stanford University School of Medicine, Stanford, CA.
Introduction: Although the liver is less immunogenic than other solid organs, most liver transplant recipients receive lifelong immunosuppression. Total lymphoid irradiation (TLI) is part of…
2015 American Transplant Congress
SBRT(Stereotactic Body Radiotherapy) to Bridge or Down-Size HCC for Liver Transplantation
N. Thai,¹ K. Tom,¹ M. Szramowski,¹ P. Abrams,¹ J. Oliva,³ D. Monga,⁴ M. Raj,⁴ D. Parda,² A. Kirichenko.²
¹Transplant Surgery, Allegheny Health Network, Pittsburgh, PA; ²Radiation Oncology, Allegheny Health Network, Pittsburgh, PA; ³Hepatology, Allegheny Health Network, Pittsburgh, PA; ⁴Medical Oncology, Allegheny Health Network, Pittsburgh, PA.
Twenty seven (27) pts with HCC and cirrhosis have been treated with SBRT with intent for liver transplantation since 2010 at Allegheny Health Network. Nineteen…
2015 American Transplant Congress
Estimation of Glomerular Filtration Rate With Serum Cystatin C Accurately Discriminates Renal Dysfunction in Liver Transplant Candidates With End-Stage Liver Disease
S. Gonzalez,¹ J. Trotter,¹ H. Szerlip,² M. Levy,³ A. Chandrakantan,⁴ A. Yango,⁴ A. Rajagopal,⁴ Y. Barri,⁴ K. Rice,⁴ M. Saim,² L. Melton,⁴ M. Emmett,² G. Klintmalm,³ B. Fischbach.⁴
¹Hepatology, Baylor Simmons Transplant Institute, Fort Worth, TX; ²Nephrology, Baylor University Medical Center, Dallas, TX; ³Transplant Surgery, Baylor Simmons Transplant Institute, Fort Worth, TX; ⁴Nephrology, Baylor Simmons Transplant Institute, Fort Worth, TX.
Background: Renal insufficiency is common in end-stage liver disease (ESLD) and is linked to survival in patients awaiting liver transplantation. Serum creatinine correlates poorly with…
2015 American Transplant Congress
Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results from the HCV-TARGET Multicenter Prospective Observational Study
J. O'Leary,¹ R. Brown,² K. Reddy,³ A. Kuo,⁴ G. Morelli,⁵ R. Stravitz,⁶ G. Everson,⁷ C. Durand,⁸ H. Vargas,⁹ P. Kwo,¹⁰ C. Frenette,¹¹ J. Peter,¹² M. Vainorius,¹² L. Akushevich,¹² D. Nelson,⁵ M. Fried,¹² N. Terrault.¹³
¹Baylor University Medical Center, TX; ²Columbia University, NY; ³University of Pennsylvania, PA; ⁴UCSD, CA; ⁵University of Florida, Gainesville, Gainesville, FL; ⁶Virginia Commonwealth University, VA; ⁷University of Colorado, CO; ⁸Johns Hopkins, MD; ⁹Mayo Clinic, AZ; ¹⁰Indiana University, IL; ¹¹Scipps Clinic, CA; ¹²University of North Carolina, NC; ¹³UCSF, CA.
The safety and efficacy of direct-acting antivirals (DAA) for HCV post-LT remain unknown. METHODS: We describe the safety and efficacy of all oral DAA-therapy for…
2015 American Transplant Congress
Combination of Non-HLA and HLA-DSA Antibodies Identifies Liver Transplants Recipients With Highest Risk for Fibrosis Progression and Mortality
J. O'Leary,¹ J. Cai,² H. Heidecke,³ L. Jennings,¹ A. Philippe,⁴ V. Harbour,¹ R. Catar,⁴ P. Terasaki,² G. Klintmalm,¹ D. Dragun.⁴
¹Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX; ²Terasaki Foundation Laboratory, Los Angeles, CA; ³Celltrend, Berlin, Germany; ⁴Nephrology & Intensive Care Medicine, Charite Berlin, Berlin, Germany.
Recent data has shown an increased risk of fibrosis progression in HCV viremic liver transplant (LT) recipients with HLA DSA in serum. However, the role…
2015 American Transplant Congress
Liver Allograft Utilization Within the United States: 2003-2013
J. Renz,¹ G. Diaz,¹ L. Ratner,² H. Yersiz,³ M. Millis,¹ J. Matthews.¹
¹Department of Surgery, University of Chicago, Chicago, IL; ²Department of Anesthesia/Critical Care, University of Chicago, Chicago, IL; ³Department of Surgery, Columbia University, New York, NY; ⁴Department of Surgery, University of California Los Angeles, Los Angeles, CA.
Objectives: 1) Evaluate liver allograft availability, utilization, and failure probability utilizing the liver donor risk index(LDRI) 2) Correlate allograft utilization with waitlist mortality and incidence…
2015 American Transplant Congress
Sofosbuvir Therapy in Early and Late Post Liver Transplant Setting: A Single Center Experience
X. Zervos,¹ D. Beltran,² B. Ismail,¹ M. Watson,¹ D. Sears,¹ A. Tzakis.¹
¹Liver Transplant, Cleveland Clinic Florida, Weston, FL; ²Pharmacy, Cleveland Clinic Florida, Weston, FL.
Background: Hepatitis C (HCV) treatment has entered a new phase of excitement with new oral therapies. Here we describe our experience of sofosbuvir (SOF) based…
2015 American Transplant Congress
Incidence and Risk Factors for Infectious Complications in Liver Transplant Patients Converted to Everolimus
A. Islam,¹ J. DeVos,² L. Teeter,³ E. Graviss,³ S. Gordon-Burroughs,¹ A. Saharia,¹ C. Mobley,¹ A. Gaber,¹ R. Ghobrial.¹
¹Department of Surgery, Houston Methodist Hospital, Houston, TX; ²Department of Pharmacy, Houston Methodist Hospital, Houston, TX; ³Department of Pathology & Genomic Medicine, Houston Methodist Hospital, Houston, TX.
AIM:Immunosuppression with an mTOR inhibitor plus calcineurin inhibitor (CNI) minimization is increasingly used in liver transplantation to protect against the nephrotoxic and neurotoxic side effects…